BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Torti C, Mazzitelli M, Longhini F, Garofalo E, Bruni A, Giancotti A, Barreca GS, Quirino A, Liberto MC, Serapide F, Matera G, Trecarichi EM, Navalesi P; IMAGES (Integrated MAnaGEment of Sepsis) Group. Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series. BMC Infect Dis 2019;19:858. [PMID: 31619209 DOI: 10.1186/s12879-019-4530-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zyryanov SK, Butranova OI, Gaidai DS, Kryshen KL. [Pharmacotherapy for acute respiratory infections caused by influenza viruses: current possibilities]. Ter Arkh 2021;93:114-24. [PMID: 33720636 DOI: 10.26442/00403660.2021.01.200551] [Reference Citation Analysis]
2 Świerczyńska M, Mirowska-Guzel DM, Pindelska E. Antiviral Drugs in Influenza. Int J Environ Res Public Health 2022;19:3018. [PMID: 35270708 DOI: 10.3390/ijerph19053018] [Reference Citation Analysis]
3 Tejada S, Campogiani L, Solé-Lleonart C, Rello J. Alternative Regimens of Neuraminidase Inhibitors for Therapy of Hospitalized Adults with Influenza: A Systematic Review of Randomized Controlled Trials. Adv Ther 2020;37:2646-66. [PMID: 32347523 DOI: 10.1007/s12325-020-01347-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Slain D. Intravenous Zanamivir: A Viable Option for Critically Ill Patients With Influenza. Ann Pharmacother 2021;55:760-71. [DOI: 10.1177/1060028020963616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]